Insider Selling: Liquidia (NASDAQ:LQDA) Insider Sells $492,765.95 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Sarah Krepp sold 13,165 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $492,765.95. Following the transaction, the insider directly owned 140,769 shares of the company’s stock, valued at approximately $5,268,983.67. This represents a 8.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Sarah Krepp also recently made the following trade(s):

• On Monday, December 1st, Sarah Krepp sold 221 shares of Liquidia stock. The stock was sold at an average price of $32.19, for a total transaction of $7,113.99.

Liquidia Stock Down 3.0%

Shares of NASDAQ:LQDA opened at $38.79 on Friday. The firm has a fifty day moving average price of $32.68 and a two-hundred day moving average price of $25.77. The company has a market cap of $3.37 billion, a price-to-earnings ratio of -26.94, a PEG ratio of 0.68 and a beta of 0.48. The company has a debt-to-equity ratio of 6.19, a current ratio of 2.20 and a quick ratio of 1.96. Liquidia Corporation has a one year low of $11.26 and a one year high of $41.57.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.41. The firm had revenue of $54.34 million for the quarter, compared to analysts’ expectations of $18.86 million. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The company’s revenue was up 1106.7% on a year-over-year basis. Analysts anticipate that Liquidia Corporation will post -1.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Liquidia

A number of hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Liquidia by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after purchasing an additional 1,700 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Liquidia by 10.7% in the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock worth $12,703,000 after purchasing an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Liquidia by 15.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after buying an additional 16,022 shares during the period. Rhumbline Advisers grew its stake in shares of Liquidia by 6.0% during the first quarter. Rhumbline Advisers now owns 85,463 shares of the company’s stock valued at $1,261,000 after buying an additional 4,811 shares during the last quarter. Finally, Ballentine Partners LLC increased its holdings in shares of Liquidia by 10.2% in the second quarter. Ballentine Partners LLC now owns 12,139 shares of the company’s stock worth $151,000 after buying an additional 1,119 shares during the period. 64.54% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on LQDA. Wells Fargo & Company started coverage on Liquidia in a report on Monday, October 20th. They set an “overweight” rating and a $31.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research note on Wednesday, October 8th. Needham & Company LLC raised their price objective on shares of Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Zacks Research raised shares of Liquidia from a “hold” rating to a “strong-buy” rating in a report on Tuesday. Finally, Jefferies Financial Group increased their target price on Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Liquidia presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.67.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).